Lisata buys Marea, raises $225M to fund cardioendocrine pipeline
What's the deal? Lisata TherapeuticsDealroom has a profile for this one. Try Dealroom → (LSTA) has acquired clinical-stage biotech Marea Therapeutics alongside a concurrent private placement expected to raise about $225 million in gross proceeds. The combined company will focus on next-generation medicines for cardioendocrine diseases.
What's the endgame? Marea brings two late-stage candidates: MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly. Lisata plans to use most of the proceeds to complete an ongoing Phase 2b trial of MAR001/005 and a Phase 2 trial of MAR002.
What are the terms? The financing consists of Series C non-voting convertible preferred stock sold to a syndicate of life sciences and institutional investors. The funding is projected to support operations into 2028.
Why now? Both trials are expected to deliver topline data in the fourth quarter of 2027, with Phase 3 registrational studies planned for each program. The capital gives Lisata the runway to reach those milestones.
The signal: The deal reshapes Lisata around a late-stage cardioendocrine pipeline, betting that two Phase 2 readouts in late 2027 will justify the raise. LSTA closed at $1.47 before the announcement, down 4.55% on the day, against a mixed biotech peer group with no uniform direction.
Read more: stocktitan.net
Image credit: Generated with Gemini
